146603-99-8

Basic information

• Product Name: 1,4-Piperidinedicarboxylic acid, 4-(2-propen-1-yl)-, 1-(1,1-dimethylethyl) 4-ethyl ester
• Synonyms: 1,4-Piperidinedicarboxylic acid, 4-(2-propen-1-yl)-, 1-(1,1-dimethylethyl) 4-ethyl ester;1-tert-butyl 4-ethyl 4-allylpiperidine-1,4-dicarboxylate;1-(1,1-Dimethylethyl) 4-ethyl 4-(2-propenyl)-1,4-piperidinedicarboxylate;Ethyl 4-allyl-1-(tert-butoxycarbonyl)piperidine-4-carboxylate;1,4-Piperidinedicarboxylic acid, 4-(2-propen-1-yl)-;1-Boc-4-allyl-4-ethoxycarbonylpiperidine
• CAS NO: 146603-99-8
• Molecular Formula: C₁₆H₂₇NO₄
• Molecular Weight: 297.39
• Product Categories: Building Blocks;C16 to C36;Chemical Synthesis;Heterocyclic Building Blocks;Piperidines
• Mol File: 146603-99-8.mol

Chemical Properties

• Boiling Point: 130-135℃/1.5mmHg
• Flash Point: >110°C
• Appearance: /
• Density: 1.020g/mLat 25℃
• Vapor Pressure: 2.97E-07mmHg at 25°C
• Refractive Index: n20/D 1.4676
• PKA: -2.29±0.40(Predicted)
• CAS DataBase Reference: 1,4-Piperidinedicarboxylic acid, 4-(2-propen-1-yl)-, 1-(1,1-dimethylethyl) 4-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Piperidinedicarboxylic acid, 4-(2-propen-1-yl)-, 1-(1,1-dimethylethyl) 4-ethyl ester(146603-99-8)
• EPA Substance Registry System: 1,4-Piperidinedicarboxylic acid, 4-(2-propen-1-yl)-, 1-(1,1-dimethylethyl) 4-ethyl ester(146603-99-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 146603-99-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,4-Piperidinedicarboxylic acid, 4-(2-propen-1-yl)-, 1-(1,1-dimethylethyl) 4-ethyl ester is used as a reactant for the synthesis of T-type calcium channel antagonists. These antagonists are essential in the development of medications targeting various cardiovascular and neurological disorders, as they help regulate the flow of calcium ions through T-type calcium channels, which play a crucial role in cellular processes.
Used in Synthesis of 2,8-Diazaspiro[4.5]decanones:
In the pharmaceutical industry, 1,4-Piperidinedicarboxylic acid, 4-(2-propen-1-yl)-, 1-(1,1-dimethylethyl) 4-ethyl ester is also utilized as an intermediate in the synthesis of 2,8-diazaspiro[4.5]decanones. These compounds are known for their potential therapeutic applications, particularly as T-type calcium channel antagonists, which can be beneficial in treating conditions related to abnormal calcium channel functioning.
Overall, 1,4-Piperidinedicarboxylic acid, 4-(2-propen-1-yl)-, 1-(1,1-dimethylethyl) 4-ethyl ester is a valuable compound in the pharmaceutical sector, playing a significant role in the development of drugs targeting T-type calcium channels and related disorders. Its versatility as a reactant and intermediate in the synthesis of various compounds makes it an essential component in the ongoing research and development of novel therapeutic agents.

InChI:InChI=1/C10H15NO4/c1-2-3-10(8(12)13)4-6-11(7-5-10)9(14)15/h2H,1,3-7H2,(H,12,13)(H,14,15)

Upstream product

• 106-95-6 allyl bromide 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 5162-44-7 1-bromo-4-butene 
• 556-56-9 allyl iodid 

Downstream Products

• 247133-32-0 4-ethoxycarbonyl-4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 4427-25-2 2-oxa-8-aza-spiro[4.5]decan-1-one 
• 154348-08-0 1,1-dimethylethyl 1-oxo-2-oxa-8-azaspiro[4,5]decane-8-carboxylate 
• 176-69-2 2-oxa-8-azaspiro[4.5]decane 
• 374794-96-4 1,1-dimethylethyl 2-oxa-8-azaspiro[4,5]decane-8-carboxylate 
• 236406-38-5 1,1-dimethylethyl 4-(2-hydroxyethyl)-4-(hydroxymethyl)-1-piperidinecarboxylate 
• 374791-95-4 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-oxa-8-aza-spiro[4.5]dec-8-yl)-1-phenyl-cyclohexyl]-propionamide 
• 374791-95-4 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-oxa-8-aza-spiro[4.5]dec-8-yl)-1-phenyl-cyclohexyl]-propionamide 
• 236406-37-4 tert-butyl 4-(hydroxymethyl)-4-(prop-2-en-1-yl)piperidine-1-carboxylate 
• 426842-70-8 4-allyl-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid 
• 1228603-43-7 4-(2-oxoethyl)-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 1350445-29-2 2-{4-[4-(tert-butyl-dimethyl-silanyloxy)-cyclohexyl]-2-fluoro-phenyl}-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester 
• 1350445-33-8 2-[2-fluoro-4-(4-hydroxy-cyclohexyl)-phenyl]-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester 
• 1259040-25-9 2-(4-([bis(1H-imidazol-2-ylmethyl)amino]methyl)benzyl)-8-(1-ethylpropyl)-2,8-diazaspiro[4.5]decane-1-carboxylic acid 

Relevant articles and documents

Preparation method of 4-oxo-8-azaspiro [4.5] dec-2-ene-8-carboxylic acid tert-butyl ester (benzyl ester)

The invention discloses a preparation method of 4-oxo-8-azaspiro [4.5] dec-2-ene-8-carboxylic acid tert-butyl ester (benzyl ester) and an intermediate thereof. The preparation method comprises the following steps: reacting a compound II with 3-bromopropylene under the action of alkali 1 to generate a compound III; dissolving the compound III in a solvent, carrying out cyclization under the action of lithium diisopropylamide, and reacting to generate a compound IV; and under the action of alkali 2, carrying out double bond shift on the compound IV to generate a compound I. The method has the advantages of easily available raw materials, simple operation and high yield, the total yield can reach more than 65%, and the method is suitable for large-scale preparation.

INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

ANTIBACTERIAL COMPOUNDS

The present invention provides a compound of the following formula and salts thereof: Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

COMPOUND HAVING SPIRO-BONDED CYCLIC GROUP AND USE THEREOF

The invention relates to a compound represented by formula (I): a salt thereof, an N-oxide thereof, or a solvate thereof (symbols in the formula are as described in the specification). The compound of the present invention exhibits very low risk of side effects and also has persistent and strong antagonistic activity against CXCR4, and is therefore useful as for example, preventive and/or therapeutic agent for inflammatory and immune diseases, infections (for example, HIV infection), diseases associated with HIV infection (for example, acquired immunodeficiency syndrome (AIDS)), cancer, cancer metastasis, psychoneurotic diseases and cardiovascular diseases (for example, retinopathy), metabolic diseases, cancerous diseases, or an agent for regeneration therapy.

Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists

The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation.

NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS

The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation.

SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention discloses and claims a series of substituted N-heteroaryl spirolactam bipyrrolidines of formula ( Wherein R1, R2, Q1, Q2, Q3, Q4, X, m, n, p and s are as described her

SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention discloses and claims respectively a series of substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides of formula (I) (Ia) and formula (Ib) as described herein. More specifically, the compounds of this invention